Ekf Diagnostics Holdings (EKF LN)

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally. It offers hemoglobin analyzers, including DiaSpect Tm, a hand-held hemoglobin analyzer; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a hemoglobin analyzer that provides quantitative laboratory quality results for blood banks, hospitals, and doctors? offices; HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples; STAT-Site M Hgb, a battery operated portable hemoglobin analyzer; and UltraCrit Plus, a hematocrit analyzer that delivers measurements for blood donor screening and sports medicine. The company also provides glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories, diabetes institutions, and sports institutions; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M �-HB analyzer for the quantitative determination of beta-hydroxybutyrate in serum or plasma. In addition, it offers Creamatocrit Plus, a system to measure creamatocrit; and pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing. Further, the company offers Sepsis testing services; and clinical chemistry reagents. It sells its products directly to GP surgeries, sports and diabetes clinics, blood banks, hospitals, laboratories, and government agencies, as well as through a network of distributors. Additionally, the company services and distributes third party company products under separate distribution agreements. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.